Search results
Results from the WOW.Com Content Network
Novo Nordisk's decision to stop selling its long-acting insulin Levemir in the United States has left some diabetes patients struggling to switch treatments, patients and doctors in a dozen U.S ...
Novo has another long-acting insulin, Tresiba, on the market. "Novo Nordisk will phase out, then permanently discontinue Levemir in the U.S. on December 31, 2024," the company said in a statement.
NNC2215 is a bioengineered glucose-sensitive insulin. The drug is designed by a team of Novo Nordisk researchers. [1] NNC2215 can sense the glucose concentration presence in blood. The protein's sensitivity is reduced when low concentration of glucose, thus reducing the risk of hypoglycemia. [2]
The top of executive of Novo Nordisk told a Senate panel Tuesday it was a "difficult choice" to discontinue the long-acting insulin Levemir but he had to do so because of market forces.
Novo Nordisk will lower the U.S. list price of some of its insulin products by up to 75%, the Danish drugmaker said Tuesday.. The change — which will take effect on Jan. 1, 2024 — follows a ...
By Sriparna Roy and Mariam Sunny (Reuters) -Advisers to the U.S. health regulator on Friday voted against the use of Novo Nordisk's weekly insulin in patients with type 1 diabetes due to risks of ...
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee is scheduled to meet on May 24 to review Novo Nordisk A/S’s (NYSE:NVO) application seeking approval for a once-weekly insulin ...
Danish pharmaceutical company Novo Nordisk announced on Tuesday it would be lowering the prices of some of its insulin products in the U.S. by up to 75 percent, becoming the second company to take ...